BMS awards 'golden tickets' to promising biotech startups

By The Science Advisory Board staff writers

November 18, 2021 -- Bristol-Myers Squibb (BMS) has given its 2021 Golden Ticket awards to five startup biotechnology companies in recognition of their pursuit of research in novel target identification, drug delivery, discovery technology platforms, or translational R&D in a variety of therapeutic research fields.

The winners are as follows:

  • RADD Pharmaceuticals (LabCentral, Cambridge, MA), a startup focused on previously undrugged cancer targets
  • Rubik Therapeutics (LabCentral, Cambridge, MA), a company developing engineered cell therapies for solid tumors by leveraging its data-driven discovery platforms
  • Waypoint Bio (BioLabs, New York, NY), a startup working to develop novel approaches to treat dosage-sensitive diseases using its genomics and machine-learning platform for high-throughput screening that can extract high-dimensional multiplexed cellular features
  • Altay Therapeutics, a preclinical-stage drug discovery company that is working to develop therapies by targeting disease-causing transcription factors
  • VastBiome (MBC BioLabs, San Francisco, CA), a DNA-first drug discovery company mapping the human gut microbiome to make medicines

The winners receive one year of fully equipped, permitted, and supported lab space for biomedical research, plus programming and networking opportunities to help advance their science and build their companies, BMS said.

BMS launched its Golden Ticket program in 2016.

Eisai, BMS to develop antibody-drug conjugate for solid tumors
Eisai and Bristol Myers Squibb (BMS) have entered a global strategic collaboration to develop and commercialize MORAb-202, an antibody-drug conjugate.
Evotec, BMS debut program to speed academic translational research
Evotec announced on May 6 a new program that aims to accelerate translational research from the U.K.'s academic life science ecosystem in collaboration...
Molecular Templates, BMS to develop engineered toxin body therapies
Molecular Templates has entered into a worldwide strategic research collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel...
BMS licenses SARS-CoV-2 neutralizing mAb combo
Bristol Myers Squibb (BMS) has entered into an agreement with Rockefeller University to license a SARS-CoV-2 neutralizing monoclonal antibody (mAb) combination.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter